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Alzheimer's diseaseAlzheimer's disease (AD) is one of the categories of neurodegenerative diseases characterized by a
conformational change of a normal protein into a pathological conformer with a high β-sheet content that
renders it resistant to degradation and neurotoxic. In AD, the normal soluble amyloid β (sAβ) peptide is
converted into oligomeric/ﬁbrillar Aβ. The oligomeric forms of Aβ are thought to be the most toxic, while
ﬁbrillar Aβ becomes deposited as amyloid plaques and congophilic angiopathy, which both serve as
neuropathological markers of the disease. An additional important feature of AD is the accumulation of
abnormally phosphorylated tau as soluble toxic oligomers and as neuroﬁbrillary tangles. Many therapeutic
interventions are under investigation to prevent and treat AD. The testing of these diverse approaches to
ameliorate AD pathology has been made possible by the existence of numerous transgenic mouse models
which each mirror speciﬁc aspects of AD pathology. None of the current murine models is a perfect match of
the human disease. Perhaps the most exciting of the therapeutic approaches being developed is
immunomodulation targeting the aggregating proteins, Aβ and tau. This type of AD therapy is currently
being assessed in many transgenic mouse models, and promising ﬁndings have led to clinical trials. However,
there is a discrepancy between results in murine models and ongoing clinical trials, which highlight
the limitations of these models and also of our understanding of the underlying etiology and pathogenesis
of AD. Because of these uncertainties, Tg models for AD are continuously being reﬁned with the aim to
better understand the disease and to enhance the predictive validity of potential treatments such as
immunotherapies.edicine,Millhauser Laboratory,
. Tel.: +1 212 263 7993; fax:+1
isniewski).
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Treatments for AD currently available provide largely symptomatic
relief with only minor effects on the course of the disease; hence,
there is an urgent need for better therapeutic interventions. Besides
immunomodulation, numerous other approaches are being studied,
which include anti-Aβ aggregation agents, secretase inhibitors/
modulators blocking Aβ production, tau aggregation blockers, agents
targeting mitochondria, stem cell therapies, and various neuropro-
tective strategies [1,2]. Currently, it appears that the greatest hope for
an intervention that will signiﬁcantly affect disease progression in the
near future comes from immunization approaches [3–5]. In AD, Tg
mouse models' Aβ-directed immunization has been hugely successful
using a wide variety of methods. Despite this, signiﬁcant unanswered
questions remain for the current and future human trials as to what is
the best design of a vaccine, what is the best target, and when shouldtherapy start. A key issue that needs to be addressed is how to target
the early initiating events in AD and not just the tombstone lesions
that are the result of a long chain of pathological processes.
2. Pathogenesis of familial and sporadic Alzheimer's disease
The diagnostic neuropathological lesions of AD are the accumu-
lation of Aβ as neuritic plaques and congophilic angiopathy, as well as
aggregation of abnormally phosphorylated tau in the form of
neuroﬁbrillary tangles (NFTs). Missense mutations in APP or in the
presenilin (PS) genes PS1 and 2 can cause early onset, familial forms of
AD (FAD) affecting b4% of AD patients. The most common form of AD
is sporadic and late onset. The dominant theory for the causation of
AD has been the amyloid cascade hypothesis [6,7]. This theory
currently suggests that accumulation of Aβ peptides particularly in a
highly toxic oligomeric form is the primary pathogenic driver that
downstream leads to tau hyperphosphorylation, NFT formation, and,
ultimately, synaptic and neuronal loss. Extensive evidence supports
this hypothesis in FAD patients and in models of FAD: (1) inherited
forms of AD linked with mutations in the APP gene or in the PS1 or 2
genes are associated with changes in APP processing that favor over
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sAβ such as Aβ1–42 [8]. (2) Down's syndrome, where there is an extra
copy of the APP gene due to trisomy 21, is associated with AD-related
pathology at a very early age [9]. (3) In transgenic and othermodels of
coexpressed amyloid β and tau, amyloid β oligomer formation
precedes and accentuates tau-related pathology, consistent with the
hypothesis that NFT formation is downstream from Aβ aggregation
[10–15]. (4) In transgenic mouse models of mutant APP over-
expression (where there is no tau pathology), therapeutic prevention
and/or removal of Aβ is associated with cognitive beneﬁts in
experimental mice [16–21]. Importantly, in transgenic mouse models
of both mutant APP and tau overexpression (with both amyloid and
tau-related pathology), prevention of Aβ pathology leads to both
amelioration of cognitive deﬁcits and attenuation of early but not late
tau pathology [22–24]. In addition, it has been shown that reducing
the level of endogenous mouse tau can prevent behavioral deﬁcits in
APP Tg mice without affecting Aβ levels [25] and that exogenous Aβ
extracted from AD Tg mice can accelerate plaque deposition in
predisposed young Tg mice [26]. However, evidence proving that Aβ
is central in the common late-onset sporadic form of AD is more
limited: (1) A correlation has been shown between biochemically
extracted Aβ peptide species from sporadic AD brains with cognitive
decline [27]. A comparison of several neuropathological features with
cognitive states in AD revealed that the strongest predictor of
cognitive dysfunction was Aβ load in the entorhinal cortex [28]. (2)
Isolated Aβ peptide dimers/oligomers from sporadic AD brains have
been documented to impair synaptic structure and function [29]. (3)
Aβ extracted from sporadic AD patients has been shown to induce
amyloid deposits when injected into transgenic mice [30]. A
signiﬁcant problem for the amyloid cascade hypothesis comes from
the autopsy data from the initial human active vaccination trial
targeting full-length Aβ. Postmortem analysis was available from nine
subjects in the active immunization arm [31]. All these individuals
showed partial or near-complete plaque removal and reduced Aβ load
compared to age-matched nonimmunized controls. Despite this, there
were no differences between placebo and active immunization groups
in terms of long-term survival outcome, time to severe dementia, and
in outcome measures such as ADAS-Cog, MMSE, or DAD. This may be
related to immunization having begun too late in the disease process;
alternatively, one can use these data to suggest that the amyloid
cascade hypothesis is an oversimpliﬁcation. A number of investigators
have suggested alternative theories, whereby accumulation of Aβ and
tau hyperphosphorylation are dual pathways both downstream from
a common upstream pathogenic deﬁcit (which remains to be
identiﬁed) [32–34]. In such a scenario, it is essential for immunother-
apy to address both of these pathologies to be highly effective. In this
review, we discuss the various approaches that have been tried to
target parenchymal amyloid deposition, vascular amyloid, oligomeric
Aβ, and tau-related pathology.
3. Overview of transgenic mouse models
3.1. A. Models of amyloid plaque deposition
The majority of successful models to generate Aβ deposits have
used transgenes for human APPwith missense mutations found in the
familial form of Alzheimer's disease (FAD; see Table 1). The ﬁrst
transgenic model (PDAPP), published by Games et al. [35], used the
Indiana mutation V717F under the control of the PDGF promoter. This
model shows a robust increase of Aβ deposition between 6 and
9 months, with the expression of APP being ∼18-fold greater than
endogenous levels. Minimal CAA can be found in these mice from
about 18 months. In old mice, the size of amyloid ﬁbrils and the
association of plaques to dystrophic neurites were shown to be
analogous to the pathology detected in patients with AD [36]. The
next AD transgenic model to be developed used the Swedish APPmutation (APP 695, K670N/M671L) under the control of the PrP
mouse promoter [37]. This model is referred to as Tg2576 and is the
most widely studied Tg model of amyloid deposition. The brain Aβ
levels start increasing at 6 months and Aβ parenchymal deposits start
developing between 9 and 12 months [37,38]. Congophilic angiopathy
can be abundant in these mice at advanced ages (N18 months) [39].
The overexpression of the mutant APP is about 5-fold. This model was
extensively used to examine the role of inﬂammation, including
astrogliosis [40], microgliosis [41], cytokine production [42], and
oxidative stress [43,44]. Several behavioral tests have shown age-
dependent impairment with cognitive tasks [18,20,37,45–47]. Further
models such as the APP23 were generated using the APP751 isoform,
expressed under control of the murine Thy-1 promoter with 7-fold
overexpression [48]. Plaques are evident at 6 months of age in the
hippocampus and cortex, with older animals having plaques also in
the thalamus and olfactory nucleus. Another line, APP22, expresses
the Swedish (APP 695, mutated K670N/M671L) and Londonmutation
(APP V717I) under control of Thy-1 promoter. These Tg mice develop
amyloid deposits at 8 months with 2-fold overexpression of APP. The
transgenic CRND8 mouse line was generated under the control of the
PrP promoter using the Swedish and the Indiana mutations (V717F)
[49]. Amyloid β deposits start quite early (from the age of 3 months)
since the two mutations involve both the β and γ secretase APP
cleavage sites. In these mice, the pathology starts in the subiculum
and the frontal cortex, followed by spread to the rest of the cortex and
hippocampus and then the thalamus, striatum, and cerebral vascu-
lature. ThemThy-1 APP 751mouse [50] is analogous in terms of spread
of the pathology to the CRND8 line. A comparison of transgenic mice
overexpressing mutated (V717I and Swedish mutation) and wild type
human APP showed that cognitive deﬁcits could be seen as early as
3 months, well before amyloid deposition, suggesting that Aβ peptide-
soluble aggregates couldbe related to thesephenotypic traits [51]. Other
single Tg lines were generated by expression of either the Flemish
(APPA692G) or the Dutch mutation (APPE693Q) [52]. These FAD
mutations are associated with extensive CAA, but in the Tg mice, they
led to behavioral abnormalities in the absence of amyloid deposition.
The next step in creating Tg models of Aβ parenchymal deposition
was to cross APP mutation lines with Tg mice expressing FAD linked
presenilin (PS) 1 mutations. More than 160mutations in PS-1, located
on chromosome 14q, and 11 mutations on PS-2, located on
chromosome 1, have been linked to FAD [53]. PS is part of the γ-
secretase complex and FAD-linked mutations are associated with an
increase in Aβ42 production [54–56]. Crossing PS1 mutation mice
with APP Tg models dramatically increases amyloid deposition,
thought to be due to increased Aβ42 production [57–60]. In these
various Tgmodels, the ratio of Aβ 40 to 42, as well as the expression of
“chaperone” proteins, affects the type and distribution of amyloid
deposits [61–63]. The critical role of Aβ42 in “seeding” amyloid
deposition was illustrated in Tg mice that express Aβ1–40 or Aβ1–42
in the absence of human APP overexpression by the fusion of Aβ42
and Aβ40 to the C-terminal end of the BRI protein [64]. Mutations in
BRI are associated with the cerebral amyloidoses of British and Danish
dementias [65,66]. The Aβ1–42 expressing mice developed extensive
cored plaques, diffuse plaques and CAA (at older ages), in contrast to
the Aβ1–40 mice that did not develop amyloid deposits at any age
[64]. Although Aβ42 appears to be essential for seeding, Aβ40 can
inﬂuence the amount of CAA, perhaps related to the fact that the
major biochemical component of CAA is Aβ40 [67].
The expression of several Aβ binding proteins can also inﬂuence
Aβ deposition and clearance. In particular, the expression of
apolipoprotein E (apoE) isoforms is a signiﬁcant factor [63,68].
Many studies have shown that the inheritance of the apoE4 allele is
the single most important genetic risk factor for late-onset AD
identiﬁed so far [63,68]. The role of apoE in AD is complex with it
being involved in both the aggregation state of Aβ and its clearance
[62,63,68,69]; however, one suggested role for apoE has been as a
Table 1
Summary of some reported AD Tg mouse models developed, with the approximate timing of parenchymal and vascular amyloid deposition, as well as timing of cognitive deﬁcits (abbreviations: Morris water maze [MWM], radial arm maze
[RAM], Barnes maze [BM], spontaneous alternation Y-maze [SAYM]).
Transgenic Line Mutations Isoforms Promotor Expression level
of APP transgene
Neuron
loss
CAA
severity
Age at onset of cognitive
deﬁcit and test used
Time of development
of cerebral amyloid
angiopathy
Age at which Aβ
plaque deposits start
Reference
PDAPP V717F 695 PDGF-β promoter. 18-fold − + 6 months (MWM) 24 months 6 months [35]
Tg2576 KM670/671 N 695 Hamster PrP 5-fold − + 9 months (MWM) 16 months 9-12 months [37]
APP23 KM670/671 N 751 Thy1.2 7-fold + ++ 3 months (MWM) 12 months 6 months [48]
APPPS1 KM670/671 N, M146L 695 PDGF-β, Hamster PrP 5 − + 8 months (RAM) 6 months 4 months [59]
APP V717I V717I 695 Thy1 2- to 5-fold − ++ 3 months (MWM) 16 months 13 months [51]
APP Flemish
APP Dutch
A682G
E693Q
770 Thy1 2- to 14-fold − + 3 months (MWM) none none [52]
Tg CRND8 KM670/671 N; V717F PrP 5 − ++ 11 weeks (MWM) 11 months 5 months [49]
Tg2576
PDAPP
Apoe−/−
KM670/671 N
V717F
695 Hamster PrP 5-fold + 12 months (MWM) N18 months 7–10 months [39]
J20 APP
Swe/Indiana
KM670/671 N
V717F
695 PDGF-β 10-fold + 7 months (MWM) 12 months 6 months [94]
APP/Swe/
Dutch/Iowa
Swedish K670N/M671L,
Dutch/Iowa E693Q/D694N
770 Thy1.2 0.5-fold − +++ 3 months (BM) 4 months 6 months (diffuse only) [101,103]
APP PS1 KM670/671 N, L166P 751 Thy1 3-fold − + 8 months (RAM) 8 months 6 weeks [60]
APPSLPS1KI APP K670N/M671L (Swedish)+
V717I (London) and PS1
M233T+L235P
751 Thy1 5-fold ++ + ? 8 months 2.5 months [88]
5XFAD APP K670N/M671L (Swedish)+
I716V (Florida)+V717I (London)
and PS1 M146L+L286V
695 Thy1 Variable depending
on which line but less
than Tg2576
++ + 4 months (SAYM) 6 months 2 months [89]
APP E693Δ APP E693Δ 695 PrP 2-fold + None 8 months (MWM) None None (Aβ oligomers
accumulate intracellularly)
[236]
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Aβ [70–73]. The critical role of apoE in Aβ deposition was shown
when PDAPP and Tg2576mice were crossed to murine apoE knockout
(KO) mice resulting in a complete lack of true amyloid plaques
[74,75]. The effects of different human apoE isoforms on Aβ
deposition are somewhat more complex. In PDAPP mice expressing
human apoE, there was a marked delay in amyloid deposition
compared tomurine apoE expressingmice or apoE KOmice; however,
the apoE4-expressing mice had increased levels of Aβ deposits
compared to apoE3 mice [39,76,77]. These crosses have also been
performed using mice that express human apoE isoforms under the
control of endogenous mouse regulatory elements to examine this
issue under more physiological conditions. When these knock-in
apoE3 and apoE4 mice were crossed to Tg2576 mice or more recently
in PDAPP mice, the apoE4 mice had signiﬁcantly more parenchymal
amyloid deposition and more CAA than the apoE3 mice [78,79]. In
humans, the signiﬁcance of apoE expression has been well docu-
mented by autopsy studies and by neuroimaging, showing that
apoE4-expressing individuals have a higher amyloid burden and
glucose utilization abnormalities even in presymptomatic stages of
AD [80–83]. The expression of different apoE isoforms is an important
consideration for immunomodulation, as current human data suggest
that apoE4 carriers are more likely to experience inﬂammatory/
hemorrhagic complications from immunomodulation, and in some
clinical trials, apoE4 carriers are being excluded or are limited to lower
doses of anti-Aβ antibodies[4,5,84]. The effect of immunomodulation
in different human apoE isotype-expressing AD Tg models is a subject
of ongoing investigation.
One of the limitations of the existing Tg amyloid models is the
relative lack of neuronal loss, contrasting to what is found in AD
[41,85,86]. Three Tg lines with some neuronal loss are the APP23mice
[48,87], a line with both the Swedish and London FAD APP mutations,
along with two PS1 mutations (M233T/L235P) [88], and a model that
expresses ﬁve familial AD mutations, three of those within the APP
gene (Swedish, Florida, and London) and two within the PS1 gene
(M146L and L286V) (“Vassar” or 5xFAD Tg mice) [89]. In the APP23
mice, there is limited neuronal loss in old animals in the direct vicinity
of thioﬂavin-positive amyloid plaques in the CA1 sector of the
hippocampus. In the model described by Casas et al. [88], there is
∼50% loss in the CA1/2 sectors of the hippocampus correlating with
the accumulation of intraneuronal Aβ rather than extracellular
plaques. In the Vassar model, large pyramidal neurons in cortical
layer 5 and subiculum are lost. Synaptic markers decrease as well in
these models with age. Many other Tg lines that do not develop
extensive neuronal loss have shown age-associated synaptic degen-
eration [60,85,86,90,91]. In the widely used Tg2576 mice, synapto-
physin immunoreactivity loss occurs in 21- to 25-month-old mice
with associated electrophysiological changes suggesting synaptic
dysfunction [92]. In addition, elegant 3D multiphoton microscopy
studies in Tg2576 and APP/PS1 Tg mice have shown neurite dis-
placement, dendritic spine loss, thinning of dendrites, and dendritic
breakage adjacent to amyloid plaques, suggesting that dense-cored
amyloid plaques do contribute at least partially to the cognitive
abnormalities found in these mice [92,93]. However, it is likely that
small soluble aggregates of Aβ are amore important cause of neuronal
dysfunction since cognitive deﬁcits in these mouse lines occur well
before the appearance of widespread cored amyloid plaques. This
hypothesis is supported by a series of Tg lines produced by Mucke
et al. [94] expressing wild type and mutant APP which do not have
amyloid deposition but have age-associated synaptophysin immuno-
reactivity loss that correlates with brain-soluble Aβ levels. It should
be mentioned, however, that overexpression of APP may conceivably
have synaptotoxic effects by itself or through other APP fragments
other than Aβ. The lack of more marked synaptic and neuronal loss
in APP and APP/PS1 mice, unless multiple mutations are expressed, is
likely related to the fact that none of these Tg lines develop sig-niﬁcant tau-related pathology. Phosphorylated tau epitopes have
been noted in dystrophic neurites adjacent to cored amyloid deposits
[35,37,59]. In particular, the S199/S202 site recognized by the
monoclonal Ab AT8 is found in many mice, but not the more AD-
speciﬁc phosphorylation sites such as those at residues S396, S404,
and S422. An additional important factor determining the degree of
neuronal loss and tau pathology in Tg AD models may be the
expression of other genes that play a signiﬁcant role in disease that
are downstream from Aβ accumulation. For example, APPSw crossed
with mice with a KO of nitric oxide synthetase 2 (NOS2) have 30%
hippocampal neuronal loss that correlates with behavioral abnormal-
ities [95]. It has been recently shown that active vaccination with
Aβ1–42 with Freund's adjuvant can prevent the neuronal loss found
in these mice [96].
3.2. B. Transgenic models of vascular amyloid deposition
Most AD patients have some degree of congophilic angiopathy
(CAA) at autopsy, with approximately 20% of AD patients having
“severe” CAA [97]. Furthermore, CAA is present in about 33% of
cognitively normal elderly, control populations [98]. The population-
based Honolulu Asia Aging Study has shown a signiﬁcant correlation
between cognition and the presence of CAA [99]. Many of the Tg
models of parenchymal amyloid discussed above and listed in Table 1
also have some vascular amyloid deposition with a variable age of
onset [100]. However, the Tg model with the most extensive vascular
amyloid in association with lower levels of parenchymal amyloid is
the APPSwDI mouse that incorporates 3 APP mutations: Swedish,
Dutch E693Q, and Iowa D694N [101–103]. These Dutch and Iowa
mutations are associated with hereditary cerebral hemorrhage with
amyloidosis (HCHWA) [104,105]. The parenchymal Aβ deposits in
these mice largely do not stain with Congo red and represent
nonﬁbrillar, diffuse amyloid similar to the neuropathology of
HCHWA-Dutch [106]. A caveat with the APPSwDI mice is that the
vascular amyloid deposition is mainly in capillaries, in contrast to AD
CAA, which is primarily in arterioles with less capillary involvement.
Interestingly, in human autopsy tissue, it is the capillary CAA level that
correlates best with the presence of other AD-related pathology [107].
When the APPSwDI mice were crossed with NOS2 KOmice, there was
an increase in amyloid deposition in association with a 30% neuronal
loss in the hippocampus [96]. The Tg2576 and the APPSwDI mice with
and without NOS2 KO have been shown to have signiﬁcant blood–
brain barrier abnormalities, whichmirror what is found in AD autopsy
tissue [108]. Importantly, the neuronal loss and behavioral abnor-
malities have been shown to be preventable in the APPSwDI/NOS2 KO
mice by Aβ1–42 vaccination [96].
3.3. C. Transgenic models of tau pathology
A number of tau mutations have been reported to be associated
with frontal temporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17), but none has been shown to produce
AD pathology [109,110]. A number of transgenic mice models that
express human tau with FTDP-17 mutations have been produced
[111]. Some of these mice display neuroﬁbrillary tangles, neuronal
death, and behavioral deﬁcits [112–124]. In most of these models,
there is presumably a disruption of axonal transport due to the
mutated tau expression and aggregation that induce synaptic and
neuronal loss. In addition, one Tg mouse model that expresses a
mutated (N279K) tau shows behavioral deﬁcits without formation of
NFTs or neuronal loss [125]. The distribution of tau pathology in many
of these tauopathy models is distinct from AD, with pretangles and
tangles often prominent in regions such as the brain stem and spinal
cord, with lesser involvement of hippocampal and cortical regions
[111].
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AD) that expresses the PS1M146V, APPSwe, and TauP301L transgenes.
This model develops extracellular amyloid deposits from 6 months of
age, and tau-related pathology starting at 10 to 12 months of age
[11,126], ﬁrst in the hippocampus and then progresses to the cortex
[126]. Deﬁcits in long-term synaptic plasticity correlate with the
accumulation of intraneuronal Aβ [11]. Recently, it has been reported
that spatial and contextual learningandmemorywere affected in the3×
Tg-AD mice in an age-dependent manner, and the accumulation of
intraneuronal Aβ correlates with cognitive deﬁcits [127]. Variability in
the pathology of this model has been reported [128]. Some lines have
delayed pathology, with plaque deposition starting at 15 months [128].
To generate a more ideal model for AD, other researchers have
used a single wild-type human tau to generate a transgenic model;
however, most of these models did not develop NFTs, with the
exception of two models: one expressing ON3R wild-type tau with a
few NFTs in aged animals [116] and another with abundant NFTs that
expresses all six human tau isoforms on a knockout background for
murine tau [129,130] that develops age-related cognitive deﬁcits
[131]. The relative absence of tau pathology in mice that express wild-
type human tau is likely due to the endogenous tau inhibiting the
formation of NFT-like pathology.
Recently, a new model has been generated by crossing htau mice
(with expression of six tau isoforms) with mice expressing the M146L
PS1 mutation [57]. This model maintained on a mouse tau knockout
background shows earlier and more advanced tau pathology than the
htaumodel anddevelopsmore severe cognitivedeﬁcits aswell [132,133].
4. Immunotherapy targeting parenchymal amyloid deposits
4.1. Active immunization
Supporting data for AD immunotherapy initially showed that anti-
Aβ antibodies could inhibit Aβ peptide ﬁbrillization/oligomerizaton
and prevent cell culture-based neurotoxicity [134,135]. This leads to
vaccination of AD Tg mice with Aβ1–42 or Aβ homologous peptides
coinjected with Freund's adjuvant, which demonstrated striking
reduction in Aβ deposition and, as a consequence, elimination of
behavioral deﬁcits (Table 2) [16–21]. This has also been done with Aβ
encoding DNA vaccines and Aβ peptide fragment (EFRH) phage
vaccines [136–138]. Similar effects on Aβ load and behavior have been
demonstrated in AD Tg mice by peripheral injections of anti-Aβ
monoclonal antibodies indicating that the therapeutic effect of the
vaccine can be based primarily on eliciting a humoral response
[139,140]. In the initial preclinical studies, no toxicity was evident inTable 2
This table shows a summary of some of the active and passive immunization approaches th
Model Antigen or antibody
PDAPP (V717F) Aβ1–42
APP (V717F) Aβ1–42
APP (V717F) Antibodies to Aβ1–6, Aβ3–6
APP (V717F Antibody to Aβ13–28
APP (V717F) Antibody to Aβ 4–10
APP(K670N, M671L, V717F) Tg CRND8 Aβ1–40 and Aβ1–42 Speciﬁc a
APP(K670N, M671L), Tg 2576 Aβ encoding DNA vaccine
APP(K670N, M671L), Tg 2576 Recombinant adenoassociated
expressing Aβ1–21
APP(K670N, M671L), Tg 2576 Antibody to oligomeric Aβ
APPK670N, M671L V717F (CDND8)mice,
APP K670N, M671L,PS1 M146L
Aβ1–42
APP(K670N, M671L), Tg 2576 K6Aβ1–30
APP(K670N, M671L), Tg 2576 K6Aβ1–30[E18E19]
Aβ1–30[E18E19]
APP(K670N, M671L), Tg 2576 K6Aβ1–30
APP(K670N, M671L), Tg K6Aβ1–30 × 4
APPAwDI/NOS2−/− Aβ1–42the treated mice; however, some investigators suggested that use of
nonﬁbrillogenic, nontoxic Aβ homologous peptides along with
approaches that stimulate primarily humoral, Th2 immunity, in
contrast to a primary Th1 cell-mediated response might reduce
potential toxicity [141–143]. The dramatic biological effect of
vaccination in preclinical testing encouraged Elan/Wyeth in April
2000 to launch a randomized, multiple-dose, dose-escalation, double-
blind phase I clinical trial with a vaccine designated as AN1792, which
contained preaggregated Aβ1–42 and QS21 as an adjuvant. This type
of vaccine designwas aimed to induce a strong cell-mediated immune
response, since QS21 is known to be a strong inducer of Th1
lymphocytes [144]. The initial trial was conducted in the United
Kingdom and involved 80 patients with mild to moderate AD [145].
This trial was designed to assess the antigenicity and the toxicity of
multiple-dose immunization with the full-length Aβ1–42 peptide
with the QS21. About 53% of patients developed an anti-Aβ humoral
response. During the later stages of the phase I trial, the emulsiﬁer
polysorbate 80 was added, causing a more pronounced proinﬂam-
matory Th1 response [146]. In the subsequent phase IIa trial, begun in
October 2001, 372 patients were enrolled, with 300 receiving the
aggregated Aβ1–42 (AN1792) with QS21 in the polysorbate 80
formulation. This trial was prematurely terminated in January 2002
when 6% of vaccinated patients manifested symptoms of acute
meningoencephalitis (18/298 subjects) [144,147,148]. Autopsies
performed on a limited number of trial patients suggested that
striking Aβ clearance of parenchymal plaques had occurred, similar to
what had been reported in the animal studies, conﬁrming the validity
of this approach for amyloid clearance in humans [148–153]. In these
cases, extensive areas of cerebral cortex were devoid of plaques, with
residual plaques having a “moth-eaten” appearance or persisting as
“naked” dense cores. This amyloid clearance in most cases was in
association with microglia that showed Aβ immunoreactivity,
suggesting phagocytosis. Additional striking features were the
persistence of amyloid in cerebral vessels in most patients, as well
as limited effects on tau immunoreactive NFTs and neuropil threads in
regions of cerebral cortex where plaque clearing had apparently
occurred, compared to regions without clearing [151–154]. A recent
study of ﬁve patients who had participated in the phase IIa Elan trial
showed a reduction in dystrophic neurites as well as a reduction in
PHF-1 immunolabeled NFTs, but no reduction in Alz50 or thioﬂavin-2-
positive tangles [155]. Furthermore, more neuritic dystrophy was
found associated with the dense-cored plaques that remained in the
vaccinated AD patients [155]. Hence, this initial vaccination approach
has not sufﬁciently addressed either NFT-related or vascular pathol-
ogy. Some cases also showed a deleterious T-cell reaction surroundingat have been used in different AD Tg models.
Type of immunization Reference
Subcutaneously+adjuvant [16]
Nasal [168]
Passive [139]
Passive [140,174]
Passive [175]
ntibodies Passive [176]
Intramuscularly [138]
virus vector Oral [170]
Passive [237]
Subcutaneously+adjuvant [18,19]
Subcutaneously+adjuvant [17]
Subcutaneously+adjuvant [20]
Subcutaneously+adjuvant [21]
Oral [173]
Subcutaneously+adjuvant [96]
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response. It appeared that the immune reaction triggered by
AN1792 was a double-edged sword, where the beneﬁts of a humoral
response against Aβ were overshadowed in some individuals by a
detrimental T-cell-mediated inﬂammatory response [148,156]. The
likely involvement of an excess cell-mediated response in mediating
toxicity was supported by analysis of peripheral blood mononuclear
cells from trial patients, which were stimulated in vitro with the Aβ
peptide, followed by quantiﬁcation of cytokine secretion by enzyme-
linked immunosorbent spot assay [146]. The cells of most responder
trial patients mounted IL-2- and IFN-γ-positive responses, indicative
of a class II (CD4+) Th1-type response [146]. Not all patients who
received AN1792 responded with antibody production. The majority
mounted a humoral response and showed a modest but statistically
signiﬁcant cognitive beneﬁt, demonstrated as an improvement on
some cognitive testing scales compared to baseline and a slowed rate
of disease progression compared to the patients who did not form
antibodies [145,157], although the effect on cognition was not clearly
evident when subjects from several different sites were analyzed
together [158]. The follow-up data from the Zurich cohort, who are a
subset of the Elan/Wyeth trial [157,159], indicated that the
vaccination approach might be beneﬁcial for human AD patients. In
agreement with the ﬁndings in the Zurich cohort, immune responders
with high antibody titers in the multicenter cohort scored signiﬁ-
cantly better in composite scores of memory functions as compared to
low- and nonresponders or to the placebo group of patients [146].
Active vaccination approaches under development in Tg mouse
models are aiming to avoid the excessive Th1 stimulation associated
with the human trial. Concurrently, the formulation of any active
vaccine also has to overcome the problem of immunosenescence in
the target patient population. One promising approach taken by
several investigators is to alter the sequence of the Aβ peptide
immunogen to remove or alter the major Th1 stimulator sites in the
carboxyl terminus and themiddle portion of Aβ, while focusing on the
major Th2 stimulator site in the amino terminus [20,21,142,160–162].
These Aβ homologous peptide immunogens can be combined with
various costimulator epitopes. An example of this approach is a
combination with a synthetic, non-natural Pan HLA DR-binding
epitope PADRE [162] or linkage to viral-like particles (VLPs) [163–
165] to induce a primarily humoral immune response. These can be
further combined with other immunostimulator carriers. For exam-
ple, the Aβ Th2 amino terminal epitope can be combined with PADRE
and macrophage-derived chemokine (MDC) in a DNA epitope vaccine
to drive robust Th2 responses [166]. The choice of adjuvant is also an
important consideration. The use of polysorbate 80 and a strong Th1
stimulate adjuvant (QS21) in the AN1792 trial is one likely
contributing factor to the encephalitis in a minority of patients. Use
of adjuvants such as alum that drive primarily a Th2 response is
preferable [21,167]. The route of immunization also plays an
important role. Stimulating mucosal immunity by vaccinating nasally,
via the gut or transcutaneously, has been shown to be beneﬁcial and
may favor a Th2 response [168–173].
A difﬁculty with active immunization aimed at just the removal or
prevention of parenchymal amyloid deposition is the autopsy data
from the human trial. Despite the apparent success in amyloid
clearance indicated by the limited autopsy data, the clinical cognitive
beneﬁts were very modest when the active vaccination group was
compared to the placebo group [158]. No difference between the
antibody responders and the placebo group was found on the ADAS-
Cog, Disability Assessment for Dementia, Clinical Dementia Rating
scale, MMSE, or on the Clinical Global Impression of Change. It was
only on a nine-item composite NTB that antibody responders had a
slight beneﬁt compared to the placebo group. These data can be used
to suggest that vaccination in this cohort was started too late, at a time
point when irreversible neurodegeneration has already occurred;
hence, tau-related pathology was largely unaffected by vaccination,and thus, the cognitive beneﬁts were small. Alternatively, it can be
suggested that the amyloid cascade hypothesis must be an oversim-
pliﬁcation of the pathogenesis of sporadic AD. The latter view is
supported by the follow-up study of the 80 patients in the initial
phase I AN1782 trial, of whom 8 came to autopsy [31]. This study
showed that despite evidence of very signiﬁcant amyloid plaque
removal in 6 out of the 8 autopsy subjects, which correlated with the
anti-Aβ titer, in the overall group, there was no evidence of improved
survival or attenuation of dementia progression [31].
4.2. Passive immunization
The easiest way to fulﬁll the goal of providing monoclonal anti-Aβ
antibodies without risk of uncontrolled Th1-mediated autoimmunity
is by passive transfer. AD Tg model mice treated this way had a
signiﬁcantly reduced Aβ level and demonstrated cognitive beneﬁt
[139,140,174–176]. Potential problems with passive immunization
include the need for repeated injections in a chronic disease, high cost,
proper selection of antigen targets, blood–brain barrier penetration,
the risk of hemorrhages, and the development of an immune response
to the injected antibodies. Several passive immunization trials are
underway with the most advanced being the phase III bapineuzumab
trial begun in December 2007 [4]. The phase II trial using this anti-Aβ
monoclonal antibody was a randomized, double-blind, placebo-
controlled trial testing 3 doses in 240 participants. In each of the
escalating doses of the antibody, approximately 32 subjects received
active agent and 28 placebos. Although the study did not attain
statistical signiﬁcance on the primary efﬁcacy end point in the whole
study population, in the subgroup of non-apoE4 carriers, clinically
signiﬁcant beneﬁts were documented using a number of scales
including the Mini Mental State Examination (MMSE) and the
Alzheimer's Disease Assessment Scale Battery, during the 18-month
trial period. In addition, among non-apoE4 carriers, evaluation of the
MRI results showed less loss of brain volume in treated versus control
patients. However, it was reported that some patients in the
treatment group developed vasogenic edema, a signiﬁcant adverse
reaction. The phase III trial is targeting to recruit 800 patients and run
until December 2010.
A particular concern in association with passive immunization is
cerebral microhemorrhage. The mechanism of this hemorrhage is
thought to be related to Aβ deposition in the form of congophilic
amyloid angiopathy (CAA) that causes degeneration of smooth
muscle cells and weakening of the blood vessel wall. A number of
reports have shown an increase in microhemorrhages in different AD
mouse models following passive intraperitoneal immunization with
different monoclonal antibodies with high afﬁnity for Aβ plaques and
CAA [177–179]. Microhemorrhages following active immunization in
animal models have also been reported in three studies [96,180,181].
In particular, in the APPSwDI/NOS2 KO mouse model with the most
extensive vascular amyloid, vaccination with Aβ1–42, while reducing
the amyloid burden in association with behavioral beneﬁts, led to a
marked increase in microhemorrhages [96]. While this increase in
microhemorrhages does not appear to be symptomatic in the mouse
models, this would bemuch less likely in humans. Strategically placed
microhemorrhages in patients have been shown to correlate with
cognitive deﬁcits [182,183]. Interestingly, gentler clearance of Aβwith
immunogens eliciting moderate antibody response may prevent
further cerebral bleeding. For example, vaccination of the Tg2576
model with an Aβ derivative, K6Aβ1–30, reduced Aβ burden and
improved cognition without increase in microhemorrhages [21].
In transgenic mouse models, Aβ antibodies can in theory both
prevent the deposition of vascular amyloid and remove it, with the
former scenario contributing to vascular repair, whereas the latter
may potentially promote bleeding. However, clearance of parenchy-
mal Aβ complicates the picture because several mouse studies suggest
it may lead to enhanced vascular amyloidosis, thereby canceling any
Table 3
Shows studies of active immunization directly targeting tau pathology.
Tg model used Immunogen Route of immunization Reference
P301L tau Tau Peptide 379–408,
phosphorylated at
Ser 396, Ser 404
Subcutaneously with
alum adjuvant
[203]
Human tau PS1 Tau Peptide 379–408,
phosphorylated at
Ser 396, Ser 404
Subcutaneously with
alum adjuvant
[233]
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hand, the autopsies from the AN1792 trial indicated no clearance of
vascular amyloid, and in one of these cases, numerous cortical bleeds
were found, which are typically rare in AD patients, [150]. This is an
important issue since CAA is present in virtually all AD cases, with
approximately 20% of AD patients having “severe” CAA [97]. The need
for vascular repair and regeneration during Aβ immunotherapy
represents another argument for early treatment as well as an
argument favoring subtle clearance over a longer period.
5. Immunotherapy targeting tau pathology
Neuroﬁbrillary tangles (NFTs) are intraneuronal inclusion bodies
that consist of an accumulation of paired helical ﬁlaments (PHFs),
which, are mainly composed of abnormally phosphorylated tau. NFTs
are a major pathologic hallmark of AD. Recently, there has been an
increased focus on phosphorylated tau as an immunotherapeutic
target [184–187]. In the CNS, human tau is expressed in six isoforms
arising from alternative mRNA splicing from a single gene on
chromosome 17q21, containing 16 exons [188,189]. The size range
of the six isoforms is between 352 and 441 amino acids, which differ
by the absence or presence of 29 (exon 2) or 58 (exon 2+exon 3)
amino acids inserts in the amino-terminal. The carboxy-terminal half
of tau contains three or four semihomologous repeats of 31 or 32
amino acids, encoded by exon 10. The repeats (3R, 4R) correspond to
the microtubule-binding region of protein tau. Stabilization of
microtubules by tau is essential for the maintenance of neuronal cell
morphology and for transport within the neuron. In addition, tau has
other roles such as interactions with kinesin-1 and the complex
dynactin/dynein [190,191]. Tau also plays a crucial role in neuronal
cell architecture by interacting with the plasma membrane as well as
cytoskeleton proteins such as actin, spectrin, and neuroﬁlament
proteins. Several mutations have been detected in the tau gene in
FTDP-17 and other tauopathies; however, none has been linked to AD
[109]. Most of these mutations affect the binding of tau to micro-
tubules or enhance the aggregation of tau into ﬁbrils. Other intronic
mutations that affect the splicing of exon 10 induce an increase of
isoformswith four repeats. In AD, tau is hyperphosphorylated atmany
phosphorylation sites with nine phosphates per molecule in compar-
ison to normal brain tau that has two to three phosphorylated
residues [192]. Other studies suggested that changes in tau splice
forms are related to neurodegeneration. In some animal models
expressing mutated tau, there is an increase of 4R versus 3R tau [193].
The functional signiﬁcance of a shift in the 3Rtau/4Rtau ratio remains
unclear, but four-repeat tau binds microtubules with a higher afﬁnity
than three-repeat tau [194].
Normal tau and PHF tau differ in molecular weight and banding
pattern. Normal tau has six bands between 45 and 68 kDa, while PHF-
tau has four bands between 60 and 74 kDa [195,196]. The diversity
of tau isoforms is related to various posttranslationalmodiﬁcations such
as phosphorylation, glycosylation, glycation, ubiquitination,
and nitration [197]. Tau has multiple phosphorylation sites that have
been characterized using phospho-tau-dependent antibodies. Of the 85
potential phosphorylated sites, 71 have been shown to be phosphor-
ylated in physiological or pathological conditions [198,199]. More than
20 protein kinases have been implicated in the phosphorylation of tau
proteins, with glycogen synthase kinase-3β (GSK-3β) and cyclin-
independent kinase (cdk5) thought to play the most important role in
phosphorylation under pathological condition [198–201].
Recently, it has been shown that active immunization of
homozygous Tg JNPL3 P301L mice [202] with a phospho-tau peptide
(containing the phosphorylated PHF-1 epitope Ser 396, Ser 404) for
3–6 months could reduce tau-related pathology (Table 3) [203]. This
particular phospho-epitope was chosen because of its immunogenic-
ity and prominent involvement in tau pathology [187]. Histological
and biochemical analyses showed a reduction of aggregated tau in thebrain and improved performance on motor tasks [203]. Motor
impairments are prominent in this model as tau pathology is
particularly advanced in brain stem and spinal cord. This study clearly
documented that it is possible to reduce tau-related pathology with
active immunization. Puriﬁed antibodies from high-titer mice entered
the brain and neurons following an intracarotid injection and bound
to pathological tau.
At ﬁrst examination, it is difﬁcult to understand how an antibody
response to a protein, which is accumulating intracellularly, can have
beneﬁcial effects. However, such an outcome is supported by a study
of immunization in a Parkinson's disease transgenic mouse model
with α-synuclein showing a reduction of intracellular α-synuclein
aggregates [204]. Another study has shown that antibodies against Aβ
can be internalized in AD neuronal culture models of Aβ accumulation
and clear intraneuronal Aβ aggregates via the endosomal–lysosomal
pathway [205]. Furthermore, recent evidence has shown that
extracellular tau aggregates can be internalized and promote the
ﬁbrillization of intracellular full-length tau in a tissue culture model
[206]. In addition, injection of ﬁbrillar tau brain extract into the brains
of transgenic wild-type expressing mice can induce the formation of
human tau into ﬁlaments, as well as the spread of pathology from the
site of injection into neighboring brain regions [207]. This type of
“infectivity” of abnormal protein conformation from outside the cell
has also been demonstrated for polyglutamine aggregates [208] and
is well characterized in prion disease [209,210]. Aβ has also been
shown to have such “infectious” properties in vivo, being able to
induce an acceleration of both further Aβ and tau-related pathology
[13–15,26,211,212]. Hence, if the spread of PHF pathology in AD can
occur via such a prion-like mechanism, antiphosphorylated tau
antibodies would not need to enter cells to be effective.6. Immunotherapy by stimulation of the innate immune system
An alternative, nonmutually exclusive approach to enhance
vaccine design is to stimulate innate immunity and enable micro-
glia/macrophages to clear amyloid and/or NFTs. More than 20 years
ago, H. Wisniewski noted that while brain-resident macrophages
were unable to phagocytose amyloid, brain-inﬁltrating macrophages
are plaque-competent [213]. A number of recent studies suggest that
only a small percentage of plaques are associated with peripheral
origin macrophages and that these are required for plaque clearance
[214–216]. Vaccination approaches based on this knowledge are now
being developed. Stimulation of peripheral macrophages to enter the
CNS and phagocytose amyloid has been achieved by stimulation of the
Toll-like receptor 9 using unmethylated cytosine–guanosine oligonu-
ceotides (CpG) [217,218], via blockade of the CD40/CD40L interaction
[219] and by blockade of TGFβ-Smad2/3 innate signaling pathway
[220]. Signiﬁcantly, amyloid clearance by CpG stimulation was
effective against CAA and parenchymal amyloid without any
associated increase in cerebral microhemorrhages [217]. These innate
immunity stimulatory approaches can be used alone or in combina-
tion with adaptive immunity stimulation. Stimulating the innate
immune system has the added potential advantage that it could be
effective against both Aβ and tau-related pathologies. Studies to
854 T. Wisniewski, E.M. Sigurdsson / Biochimica et Biophysica Acta 1802 (2010) 847–859address whether stimulation of the innate immune system will be
effective to inhibit tau-related pathology are underway.
7. Immunization targeting Aβ and tau oligomers
Abundant evidence both in vivo and in vitro suggests that the most
toxic species of Aβ are oligomers or Aβ-derived diffusible ligands
(ADDLs) [221,222] with a similar line of evidence suggesting that tau
oligomers are the most toxic form of phosphorylated tau [120,186].
Active vaccination or use of monoclonal antibodies that speciﬁcally
target Aβ oligomers, tau oligomers, or preferably bothwould be an ideal
way to block AD-related toxicity. A small number of preclinical studies
targeting Aβ oligomers suggest that this methodology is potentially
powerful and in the need of further development [223–227]. However,
various proteins/peptides exist to some extent in a β-sheet conforma-
tion, which raises concerns about possible side effects of this otherwise
promising approach [228]. On the other hand, indiscriminate clearance
of all forms of Aβmay not be ideal because emerging evidence suggests
thatmonomeric Aβ peptides have normal physiological functions in the
brain such as neuroprotection and modulating LTP [229,230], with
normally phosphorylated tau also having a role [185]. Targeting only
oligomeric Aβ or tau would avoid potential interference with these
physiological functions. A novel immunotherapeutic approach is to
target the shared abnormal β-sheet conformation of amyloid proteins
using conformationally speciﬁc antibodies or active immunization that
favors such a conformational response [223,224,231,232]. Such an
approach has the advantage that both Aβ and tau-related pathologies
would be addressed concurrently.
8. Conclusions
Many studies are underway in AD Tg mouse models aiming to
improve the efﬁcacy and safety proﬁle of immunomodulation in
patients. Approaches that concurrently address the three AD-related
pathologies, namely, neuritic plaques, CAA, and NFTs, will have the
greatest chance of success. Abnormal protein conformation is thought
to be not only the underlying pathogenesis of AD but also of a long list
of neurodegenerative conditions, such as prion disease, Parkinson's
disease, and Huntington's chorea, with immunomodulation having
the potential to be a disease-altering therapeutic approach for all
these disorders [5]. For example, it has been shown that prion-
directed mucosal vaccination can prevent infection from an exoge-
nous source [234,235]. The development of safe and effective
immunomodulation methods in Tg models that direct the immune
system to clear highly toxic abnormal oligomeric conformers that
underlie the pathogenesis of multiple neurodegenerative diseases has
the greatest potential to halt the progression of a wide spectrum of
human neurodegenerative conditions.
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